| Objective:To investigate current situation of secondary prevention among patients with established coronary heart disease (CHD) in China, mainly describe the degree and determinants of evidence-based medication use.Methods:In the context of an international multi-centre clinical trial being undertaken in China, high-risk patients with CHD were screened in51highest-rank hospitals in14cities. The characteristics collected by electronic questionnaire were described and analyzed.Results:13078patients with established CHD were interviewed between June2007and Oct2009. The use of cardioprotective medication was:statins57.4%; antiplatelets87.6%; angiotensin-converting enzyme inhibitors(ACEI)/angiotensin-receptor blockers(ARB)45.8%; β-blockers60.1%. Fewer than one quarter (23.6%) of patients were on all of the four cardioprotective medication combined, and even there were7.2%of patients did not take any of them when interviewed.Conclusions:This findings highlight large gap between clinical practice and the clinical guidelines for the secondary prevention among high-risk CHD patients. It remains a major challenge for healthcare professionals and policy makers to resolve this problem rapidly. |
PDF Full Text Request